Information  X 
Enter a valid email address

VASTox plc (SUMM)

  Print      Mail a friend

Thursday 22 March, 2007

VASTox plc

Director/PDMR Shareholding

VASTox plc
22 March 2007



                                   VASTox plc

                          ('VASTox' or 'the Company')

                            Directors' Shareholdings

Oxford, UK, 22 March 2007 - VASTox plc (AIM: VOX) has been notified that Dr
Colin Wall, a Non-executive Director of the Company, has today purchased 38,000
ordinary shares of 10p each ('Ordinary Shares') at a price of 127 pence per
share. Dr Wall now holds a total of 74,000 shares representing 0.15 per percent
of the issued share capital.

Colin Wall joined the VASTox Board of Directors in September 2006 as a
Non-executive Director and Chairman of the Remuneration Committee.


                                    - ends -


For more information, please contact:

  VASTox
  Steven Lee, PhD, Chief Executive Officer              Tel: +44 (0)1235 443951
  Darren Millington, Chief Financial Officer

  Citigate Dewe Rogerson                                Tel: +44 (0)207 638 9571
  Mark Swallow / David Dible / Valerie Auffray


About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX


Further information about the company is available at www.vastox.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange